Current Rheumatology Reports

, Volume 10, Issue 2, pp 89–91 | Cite as

Clinical trials report

  • Amy Warriner
  • Kenneth G. Saag


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cramer JA, Amonkar MM, Hebborn A, Altman R: Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005, 21:1453–1460.PubMedCrossRefGoogle Scholar
  2. 2.
    Bischoff-Ferrari HA, Willett WC, Wong JB, et al.: Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005, 293:2257–2264.PubMedCrossRefGoogle Scholar
  3. 3.
    The National Osteoporosis Foundation: America’s Bone Health: The State of Osteoporosis and Low Bone Mass. Available at Accessed February 7, 2008.Google Scholar
  4. 4.
    Centers for Disease Control and Prevention (CDC): Fatalities and injuries from falls among older adults—United States, 1993–2003 and 2001–2005. MMWR Morb Mortal Wkly Rep 2006, 55:1221–1224.Google Scholar
  5. 5.
    Reid IR, Brown JP, Burkhardt P, et al.: Intravenous zole-dronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653–661.PubMedCrossRefGoogle Scholar
  6. 6.
    Lyles KW, Colon Everic CS, Magaziner JS, et al.: Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799–1809.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Amy Warriner
  • Kenneth G. Saag

There are no affiliations available

Personalised recommendations